RxDoctor Payments Data

Maurice McCarthy, MD

Rheumatology · Winter Haven, FLNPI 1346219870

Payments from drug & device makers

$9,178in general payments, 2019–2025

Across 483 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Johnson & Johnson$1K
  • GSK$988
  • Novartis$906
  • Pfizer$822
  • UCB, Inc.$785
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$2603%
  • Food & beverage$8,74495%
  • Education$1742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,178 in reported general payments places this provider in the 50th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$625,311
Medicare patients
219
Services billed
59,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept48$542,988
RinvoqUpadacitinib44$283,756
EnbrelEtanercept20$175,292
Humira(Cf) PenAdalimumab15$104,370
Cosentyx Sensoready PenSecukinumab11$81,067
HumiraAdalimumab11$76,538
Hydroxychloroquine Sulfate185$7,875
Celecoxib175$5,806
MethotrexateMethotrexate Sodium204$4,562
Leflunomide39$1,619
Prednisone127$1,266
Raloxifene Hcl22$1,194
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$1,068
Folic Acid66$706
Simvastatin63$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$727$360,29355 claims
AmgenEnbrel$1,573$175,29220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →